In the Green: Verona Pharma Plc ADR (VRNA) Closes at 22.61, Up/Down -0.53 from Previous Day

In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

In the latest session, Verona Pharma Plc ADR (NASDAQ: VRNA) closed at $22.61 down -0.53% from its previous closing price of $22.73. In other words, the price has decreased by -$0.53 from its previous closing price. On the day, 0.73 million shares were traded. VRNA stock price reached its highest trading level at $23.24 during the session, while it also had its lowest trading level at $22.5.

Ratios:

For a deeper understanding of Verona Pharma Plc ADR’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 18.40 and its Current Ratio is at 18.40. In the meantime, Its Debt-to-Equity ratio is 0.23 whereas as Long-Term Debt/Eq ratio is at 0.22.

On August 26, 2022, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $31.Piper Sandler initiated its Overweight rating on August 26, 2022, with a $31 target price.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 03 ’24 when Rickard Kathleen A. sold 36,248 shares for $1.96 per share. The transaction valued at 71,032 led to the insider holds 2,621,552 shares of the business.

Rickard Kathleen A. sold 36,248 shares of VRNA for $80,503 on Feb 05 ’24. The Chief Medical Officer now owns 2,731,624 shares after completing the transaction at $2.22 per share. On Nov 20 ’23, another insider, Edwards Martin, who serves as the Director of the company, bought 33,736 shares for $1.84 each. As a result, the insider paid 61,973 and bolstered with 144,800 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRNA now has a Market Capitalization of 1833259520 and an Enterprise Value of 14540295168.

Stock Price History:

Over the past 52 weeks, VRNA has reached a high of $23.72, while it has fallen to a 52-week low of $11.39. The 50-Day Moving Average of the stock is 41.44%, while the 200-Day Moving Average is calculated to be 41.58%.

Shares Statistics:

For the past three months, VRNA has traded an average of 1.34M shares per day and 1236960 over the past ten days. A total of 80.44M shares are outstanding, with a floating share count of 62.41M. Insiders hold about 23.03% of the company’s shares, while institutions hold 61.14% stake in the company. Shares short for VRNA as of 1721001600 were 9634279 with a Short Ratio of 7.20, compared to 1718323200 on 7717026. Therefore, it implies a Short% of Shares Outstanding of 9634279 and a Short% of Float of 12.41.

Most Popular